Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 1.920
+0.060 (3.23%)
At close: Mar 4, 2026
Sprint Bioscience AB Market Cap
Sprint Bioscience AB has a market cap or net worth of 202.59 million as of March 4, 2026. Its market cap has increased by 90.39% in one year.
Market Cap
202.59M
Enterprise Value
75.89M
Revenue
167.17M
Ranking
n/a
PE Ratio
1.96
Stock Price
1.92
Market Cap Chart
Since November 7, 2014, Sprint Bioscience AB's market cap has increased from 62.49M to 202.59M, an increase of 224.17%. That is a compound annual growth rate of 10.94%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 4, 2026 | 202.59M | 30.61% |
| Dec 30, 2025 | 155.11M | 40.43% |
| Dec 30, 2024 | 110.46M | -8.82% |
| Dec 29, 2023 | 121.14M | 449.78% |
| Dec 30, 2022 | 22.03M | -88.47% |
| Dec 30, 2021 | 191.05M | 17.26% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Bio-Works Technologies AB | 272.42M |
| Mendus AB | 248.77M |
| AlzeCure Pharma AB | 223.51M |
| Xintela AB | 218.76M |
| Intervacc AB | 211.30M |
| Initiator Pharma | 195.09M |
| Isofol Medical AB | 193.96M |
| Magle Chemoswed Holding AB | 163.13M |